Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cardinal Health $1.15 billion notes offering
The investment-grade notes are due 2029 and 2034
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Cigna $4.5 billion senior notes offering
The senior notes are due 2029, 2031, 2034 and 2054
Novo Nordisk class certification victory
The district court denied plaintiffs’ motion for class certification in its entirety
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition